4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $29.88 Consensus Target Price from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $29.8750.

A number of analysts have commented on FDMT shares. Chardan Capital reiterated a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. Royal Bank Of Canada boosted their price objective on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. The Goldman Sachs Group set a $33.00 target price on 4D Molecular Therapeutics in a research note on Friday, May 8th. Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th.

Insider Activity

In related news, insider David Kirn sold 114,746 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62. Following the sale, the insider owned 942,485 shares of the company’s stock, valued at $9,867,817.95. The trade was a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Scott Bizily sold 9,810 shares of the stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the transaction, the insider directly owned 8,617 shares of the company’s stock, valued at $103,404. This trade represents a 53.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 126,478 shares of company stock worth $1,338,369. 7.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC boosted its stake in 4D Molecular Therapeutics by 164.4% in the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock valued at $34,726,000 after buying an additional 2,882,508 shares in the last quarter. State Street Corp lifted its holdings in shares of 4D Molecular Therapeutics by 197.5% during the fourth quarter. State Street Corp now owns 2,688,880 shares of the company’s stock valued at $20,167,000 after acquiring an additional 1,785,106 shares during the period. RA Capital Management L.P. lifted its holdings in shares of 4D Molecular Therapeutics by 23.9% during the fourth quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after acquiring an additional 1,090,000 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in shares of 4D Molecular Therapeutics by 605.8% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company’s stock valued at $9,264,000 after purchasing an additional 1,060,156 shares in the last quarter. Finally, Evergreen Quality Fund GP Ltd. acquired a new stake in shares of 4D Molecular Therapeutics in the 4th quarter valued at $7,136,000. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT opened at $12.89 on Friday. The firm’s 50-day moving average is $10.14 and its 200-day moving average is $9.31. The company has a market cap of $673.89 million, a price-to-earnings ratio of -5.02 and a beta of 2.70. 4D Molecular Therapeutics has a 52-week low of $4.11 and a 52-week high of $14.00.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The company had revenue of $3.05 million during the quarter, compared to the consensus estimate of $2.59 million. Equities analysts predict that 4D Molecular Therapeutics will post -4.14 EPS for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.